Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.50 |
| ▸ | GABRD | O14764 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.50 |
| ▸ | GABRE | P78334 | 3/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23674282 | 0.82 | IDO1 (0.38) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30445660 | 0.82 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2804722 | 0.82 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15567438 | 0.81 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7220645 | 0.81 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4792319 | 0.81 | NQO2 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL6331664 | 0.77 | POLB (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL70795 | 0.75 | SMN1; SMN2 (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28139785 | 0.74 | CFTR (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9491457 | 0.73 | SMN1; SMN2 (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300466-B1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8410128-B2 | Triazolopyridine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8338604-B2 | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2307411-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| EP-2300466-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009155389-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155388-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077243-A1 | Triazolopyridine Compounds Useful As Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K8 | GABRP 1531/4885GABRD 1669/4885GABRA1 2618/4885 |
| US-20110288085-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP4K2, MAPKAPK2, MAP3K5 | GABRP 1224/4885GABRD 2369/4885GABRA1 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.